Skip to main content
SpringerLink
Log in

Lipid-Modifying Therapy and Attainment of Cholesterol Goals in Hungary

The Return on Expenditure Achieved for Lipid Therapy (REALITY) Study

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and objective: Cardiovascular disease is a leading cause of death in Eastern Europe. Few studies on cholesterol goal achievement have been conducted in Hungarian clinical settings. This study set out to evaluate lipid-modifying therapy practices and their effects on total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) goal attainment in Hungarian patients with coronary heart disease (CHD), CHD risk equivalents, or ≥2 coronary risk factors.

Methods: This multicentre observational study involved patients receiving lipid-modifying therapy who were under the care of general practitioners (n = 300) or specialists (n = 140). Physician questionnaires were used to collect data on baseline patient characteristics, including laboratory parameters. Using validated cardiovascular risk assessment measures, patients were stratified into high-risk (10-year absolute coronary risk >20%; n = 367) and lower risk groups (n = 73). Cholesterol goals were TC <4.5 mmol/L (<175 mg/dL) and LDL-C <2.5 mmol/L (<100 mg/dL) for the high-risk group and TC <5.0 mmol/L (<193 mg/dL) and LDL-C <3.0 mmol/L (<117 mg/dL) for those at lower risk.

Results: Among 440 patients (n = 312 with CHD or CHD risk equivalents), 374 (85%) were initiated on HMG-CoA reductase inhibitors (statin monotherapy), 44 (10%) received fibric acid derivatives and 22 (5%) received combination regimens. Although >50% of patients needed >35% TC lowering to reach goal, <10% of patients received high or very high potency lipid-modifying regimens or combination regimens initially. A total of 116 (26.4%) patients achieved their TC goals after ≥1 year of treatment, including 27.9% of patients with CHD/risk equivalents and 22.7% of those with risk factors only. Sixty-six (15%) patients achieved goal on initial lipid-modifying regimens, while a further 50 (11.4%) achieved goal following treatment changes, including upward dosage adjustments.

Conclusion: Approximately 74% of Hungarian patients receiving lipid-modifying therapy in our study did not achieve cholesterol goals. The proportion of patients realising their TC goals was higher in those treated by specialists but still did not exceed one-third.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Fig. 2
Table IV
Table V
Fig. 3
Table VI
Fig. 4

Similar content being viewed by others

References

  1. World Health Organization. Atlas of heart disease and stroke: types of cardiovascular disease 2005 [online]. Available from URL: http://www.who.int [Accessed 2006 Apr 10]

  2. Petersen S, Peto V, Rayner M, et al. European cardiovascular disease statistics: 2005 edition [online]. Available from URL: http://www.ehnheart.org/cms/site/showdoc.asp?.id = 5883 [Accessed 2006 May 23]

  3. European Heart Network. CVD statistics: statistical data about cardiovascular disease in Europe [online]. Available from URL: http://www.ehnheart.org/content/sectionintro.asp?.level0 = 1457 [Accessed 2006 May 23]

  4. Józan P. Fordulat a halandósában és az életkilátásokban, epidemiológiai korszakváltás Magyarországon? New trends in mortality and life expectancy: epidemiologic transition in Hungary? Orv Hetil 2003; 144: 451–60

    PubMed  Google Scholar 

  5. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistic—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85–151

    Article  PubMed  Google Scholar 

  6. Ministry of Health, Hungary (Budapest). Johan Béla National Programme for the Decade of Health [online]. Available from URL: http://www.eum.hu/eum/eum_angol.headpage?.pid = DA_22059. 2003 [Accessed 2006 Jun 12]

  7. EUROASPIRE (European Action on Secondary Prevention through Intervention to Reduce Events) Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569–82

    Article  Google Scholar 

  8. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–72

    Article  Google Scholar 

  9. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995–1001

    Article  Google Scholar 

  10. Ose L, Skjeldestad FE, Bakken IJ, et al. Lipid management and cholesterol goal attainment in Norway. Am J Cardiovasc Drugs 2006; 6: 121–8

    Article  PubMed  CAS  Google Scholar 

  11. Van Ganse E, Laforest L, Alemao E, et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005; 21: 1389–99

    Article  PubMed  Google Scholar 

  12. Van Ganse E, Souchet T, Laforest L, et al. Ineffectiveness of lipid-lowering therapy in primary care. Br J Clin Pharmacol 2005; 59: 456–63

    Article  PubMed  Google Scholar 

  13. Goettsch WG, Yin DD, Alemao E, et al. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Curr Med Res Opin 2004; 20: 1025–33

    Article  PubMed  CAS  Google Scholar 

  14. Garcia Ruíz FJ, Ibanez AM, Perez-Jimenez F, et al. Current lipid management and low cholesterol goal attainment in common daily practice in Spain: the REALITY study. Pharmaco-economics 2004; 22Suppl. 3: 1–12

    Google Scholar 

  15. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459–67

    Article  PubMed  CAS  Google Scholar 

  16. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83: 1303–7

    Article  PubMed  CAS  Google Scholar 

  17. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605–10

    Article  PubMed  CAS  Google Scholar 

  18. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100: 197–204

    Article  PubMed  CAS  Google Scholar 

  19. Krobot KJ, Yin DD, Alemao E, et al. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. Eur J Cardiovasc Prev Rehabil 2005; 12: 37–45

    Article  PubMed  Google Scholar 

  20. Krobot KJ, Yin DD, Alemao E, et al. LDL-cholesterol levels attained on lipid-lowering therapy: the relationship to pretreatment CHD risk and pretreatment LDL-cholesterol (REALITY-Study Germany) [abstract]. Atherosclerosis 2004; 5: 129

    Article  Google Scholar 

  21. Karády I. A kardiovaszkularis terapias konszenzus konferencia lipidcsokkento ajanlasai az ateroszklerozis prevenciojara es kezelesere (The lipid lowering recommendations of the Hungarian National Consensus Conference). Metabolizmus 2004; 2: 8–12

    Google Scholar 

  22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502

    PubMed  CAS  Google Scholar 

  23. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207–13

    Article  PubMed  CAS  Google Scholar 

  24. Bautista MC, Engler MM. The Mediterranean diet: is it cardioprotective? Prog Cardiovasc Nurs 2005; 20: 70–6

    Article  PubMed  Google Scholar 

  25. Trichopoulou A, Bamia C, Trichopoulos D. Mediterranean diet and survival among patients with coronary heart disease in Greece. Arch Intern Med 2005; 165: 929–35

    Article  PubMed  Google Scholar 

  26. Trichopoulou A, Orfanos P, Norat T, et al. Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study. BMJ 2005; 330: 991–7

    Article  PubMed  Google Scholar 

  27. Kern J, Strnad M, Coric T, et al. Cardiovascular risk factors in Croatia: struggling to provide the evidence for developing policy recommendations. BMJ 2005; 331: 208–10

    Article  PubMed  Google Scholar 

  28. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504

    Article  PubMed  CAS  Google Scholar 

  29. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–39

    Article  PubMed  Google Scholar 

  30. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23: 1190–201

    Article  PubMed  CAS  Google Scholar 

  31. Östör E, Jánosi A, Ádám Z, et al. A koszorúér-betegség msodlagos prevenciója. Helyzetkép az ezredfordulón az EUROASPIRE I–II vizsgálat magyar adatainak tükrében (Secondary prevention of coronary disease: at the turn of the millennium in light of the Hungarian data of the EUROASPIRE I–II studies). Orv Hetil 2003; 144: 2933–404

    Google Scholar 

  32. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002; 89: 268–75

    Article  PubMed  CAS  Google Scholar 

  33. Muls E, De Backer G, Brohet C, et al. The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial. Acta Cardiol 2001; 56: 109–14

    Article  PubMed  CAS  Google Scholar 

  34. Garmendia F, Brown AS, Reiber I, et al. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study). Curr Med Res Opin 2000; 16: 208–19

    PubMed  CAS  Google Scholar 

  35. Hunninghake D, Bakker-Arkema RG, Wigand JP, et al. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract 1998; 47: 349–56

    PubMed  CAS  Google Scholar 

  36. McBride P, Schrott HG, Plane MB, et al. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998; 158: 1238–44

    Article  PubMed  CAS  Google Scholar 

  37. Yarzebski J, Bujor CF, Goldberg RJ, et al. A community-wide survey of physician practices and attitudes toward cholesterol management in patients with recent acute myocardial infarction. Arch Intern Med 2002; 162: 797–804

    Article  PubMed  Google Scholar 

  38. Fornengo P, Bruno G, De Salvia A, et al. Low adherence of general practitioners to National Cholesterol Education Program guidelines for the management of hyperlipidaemia. Diabetes Nutr Metab 2000; 13: 263–8

    PubMed  CAS  Google Scholar 

  39. Foley KA, Simpson Jr RJ, Crouse III JR, et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003; 92: 79–81

    Article  PubMed  CAS  Google Scholar 

  40. Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–421

    Google Scholar 

  41. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071–80

    Article  PubMed  CAS  Google Scholar 

  42. Amarenco P, Bogousslavsky J, Callahan III A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59

    Article  PubMed  CAS  Google Scholar 

  43. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–35

    Article  PubMed  CAS  Google Scholar 

  44. De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307–16

    Article  PubMed  Google Scholar 

  45. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study. A randomized controlled trial. JAMA 2005; 294: 2437–45

    Article  PubMed  CAS  Google Scholar 

  46. Mok HY, von Bergmann K, Grundy SM. Effects of continuous and intermittent feeding on biliary lipid outputs in man: application for measurements of intestinal absorption of cholesterol and bile acids. J Lipid Res 1979; 20: 389–98

    PubMed  CAS  Google Scholar 

  47. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 2005; 102: 8132–7

    Article  PubMed  CAS  Google Scholar 

  48. Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1084–91

    Article  PubMed  Google Scholar 

  49. Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004; 148: 447–55

    Article  PubMed  CAS  Google Scholar 

  50. Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80: 587–95

    Article  PubMed  CAS  Google Scholar 

  51. Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149: 464–73

    Article  PubMed  CAS  Google Scholar 

  52. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409–15

    Article  PubMed  CAS  Google Scholar 

  53. Cruz-Fernandez JM, Bedarida GV, Adgey J, et al. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract 2005; 59: 619–27

    Article  PubMed  CAS  Google Scholar 

  54. Brohet C, Banai S, Alings AM, et al. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 2005; 21: 571–8

    Article  PubMed  CAS  Google Scholar 

  55. Farnier M, Volpe M, Massaad R, et al. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005; 102: 327–32

    Article  PubMed  Google Scholar 

  56. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99: 673–80

    Article  PubMed  CAS  Google Scholar 

  57. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125i–34i

    Article  Google Scholar 

  58. Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin 2007; 23: 767–75

    Article  PubMed  CAS  Google Scholar 

  59. Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006; 81: 1579–88

    Article  PubMed  CAS  Google Scholar 

  60. Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004; 93: 1487–94

    Article  PubMed  CAS  Google Scholar 

  61. Ballantyne CM, Lipka LJ, Sager PT, et al. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolemia. Int J Clin Pract 2004; 58: 653–8

    Article  PubMed  CAS  Google Scholar 

  62. Barrios V, Amabile N, Paganelli F, et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract 2005; 59: 1377–86

    Article  PubMed  CAS  Google Scholar 

  63. Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemia patients. Curr Med Res Opin 2006; 22: 2041–53

    Article  PubMed  CAS  Google Scholar 

  64. Goldberg AC, Sapre A, Capece R, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004; 79: 620–9

    Article  PubMed  CAS  Google Scholar 

  65. Armstrong EP, Zachry III WM, Malone DC. Cost-effectiveness analysis of simvastatin and lovastatin/extended-release niacin to achieve LDL and HDL goal using NHANES data. J Manag Care Pharm 2004; 10: 251–8

    PubMed  Google Scholar 

  66. Kashyap M, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89: 672–8

    Article  PubMed  CAS  Google Scholar 

  67. Pasternak RC, Smith Jr SC, Bairey-Merz CN, et al. ACC/AHA/ NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106: 1024–8

    Article  PubMed  Google Scholar 

  68. Athyros VG, Papageorgou AA, Merouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus usual care in secondary heart disease prevention: the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2007; 18: 220–8

    Article  Google Scholar 

  69. Erhardt LR. Barriers to effective implementation of guideline recommendations. Am J Med 2005; 118(12A): 36S–41S

    Article  Google Scholar 

  70. Grant RW, O’Leary KM, Weilbrug JB, et al. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med 2004; 164: 2343–8

    Article  PubMed  Google Scholar 

  71. Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004; 22Suppl. 3: 13–23

    PubMed  Google Scholar 

  72. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006; 296: 2563–71

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by MSP (Merck/Schering Plough) Singapore Company, LLC. Assistance in manuscript preparation was provided by Stephen W. Gutkin, Rete Biomedical Communications Corp., Ridgewood, NJ, USA. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. First Department of Medicine, Medical and Health Science Centre, University of Debrecen, Nagyerdei krt. 98, H-4012, Debrecen, Hungary

    György Paragh

  2. Second Department of Internal Medicine-Cardiology, Pandy Kalman Bekes County Hospital, Gyula, Hungary

    Lászlo Márk

  3. Fourth Department of Internal Medicine-Cardiology, Bajcsy-Zsilinszky Hospital, Budapest, Hungary

    Károly Zámolyi

  4. Fourth Department of Internal Medicine, Lipidology, Szent Imre Hospital, Budapest, Hungary

    Gyula Pados

  5. Gottsegen György National Institute of Cardiology, Budapest, Hungary

    Péter Ofner

Authors
  1. György Paragh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lászlo Márk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Károly Zámolyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gyula Pados
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Péter Ofner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to György Paragh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paragh, G., Márk, L., Zámolyi, K. et al. Lipid-Modifying Therapy and Attainment of Cholesterol Goals in Hungary. Clin. Drug Investig. 27, 647–660 (2007). https://doi.org/10.2165/00044011-200727090-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200727090-00006

Keywords

Search

Navigation